|
Jun 17
|
Trump's big beautiful bill: What the pharma industry is watching
|
|
Jun 17
|
Johnson & Johnson’s Q1 Earnings Call: Our Top 5 Analyst Questions
|
|
Jun 17
|
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
|
|
Jun 16
|
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
|
|
Jun 16
|
J&J reports results from antibody combo trial for MM patients
|
|
Jun 15
|
Pharma manufacturing 'boom' faces high costs, potential delays
|
|
Jun 15
|
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
|
|
Jun 14
|
Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma
|
|
Jun 14
|
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
|
|
Jun 14
|
Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
|
|
Jun 12
|
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
|
|
Jun 12
|
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
|
|
Jun 11
|
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
|
|
Jun 11
|
Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
|
|
Jun 11
|
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
|
|
Jun 11
|
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services
|
|
Jun 11
|
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
|
|
Jun 11
|
Why defensive stocks could be your best bet in a wild market
|